Orna Therapeutics Acquires ReNAgade Therapeutics

Danaher Acquires Precision NanoSystems

June 1, 2021

Biotechnology

Danaher Corporation has acquired Vancouver-based Precision NanoSystems (PNI), a developer of lipid nanoparticle delivery technologies and microfluidic manufacturing platforms for genetic medicines. PNI will join Danaher's Life Sciences platform to expand its capabilities in mRNA and genetic-medicine development and complement existing portfolio companies such as Cytiva and Pall.

Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics

January 9, 2026

Biotechnology

Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.

Agomab Therapeutics Acquires Origo Biopharma

December 15, 2021

Biotechnology

Agomab Therapeutics NV has completed the acquisition of Spanish biotech Origo Biopharma, integrating Origo's team and facilities in Touro and Barcelona into Agomab's organization. The deal combines Origo's organ‑restricted small‑molecule platform targeting the TGF‑β pathway with Agomab's HGF‑targeting antibody programs to broaden the combined clinical‑stage pipeline for fibrosis therapeutics.

AbbVie Acquires Capstan Therapeutics

August 19, 2025

Biotechnology

AbbVie has completed its acquisition of Capstan Therapeutics, adding Capstan's lead asset CPTX2309 — an in vivo targeted lipid nanoparticle (tLNP) anti‑CD19 CAR‑T candidate in Phase 1 for B cell‑mediated autoimmune diseases — and a proprietary tLNP RNA delivery platform. The deal strengthens AbbVie's immunology pipeline and expands its in vivo cell‑programming capabilities for RNA payload delivery.

Oragenics Acquires Odyssey Health Neurological Drug Assets

January 2, 2024

Pharmaceuticals

Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.

Novo Nordisk Acquires Dicerna Pharmaceuticals

November 18, 2021

Biotechnology

Novo Nordisk agreed to acquire Dicerna Pharmaceuticals for $38.25 per share, representing an enterprise equity value of approximately $3.3 billion, to expand its RNAi capabilities. The acquisition builds on a 2019 research collaboration and brings Dicerna's GalXC RNAi platform and pipeline into Novo Nordisk to accelerate development of RNAi therapeutics across cardiometabolic, liver and rare disease indications. The tender offer completed in December 2021 and Dicerna is now a wholly owned subsidiary of Novo Nordisk.